Latest Articles

Publication Date
NHRC takes suo motu cognizance of the reported corporal punishment fracturing a student's shoulder at a government-run primary school in the Gautam Budh Nagar district, Uttar Pradesh - India Education Diary

NHRC takes suo motu cognizance of the reported corporal punishment fracturing a student's shoulder at a government-run primary school in the Gautam Budh Nagar district, Uttar Pradesh India Education Diary

Published: Aug. 19, 2025, 7:47 a.m.
Synchronous Primary Vulvar Squamous Cell Carcinoma and Ciliated Cell Variant of Endometrioid Adenocarcinoma Arising in an Endometrial Polyp: A Rare Dual Malignancy - Cureus

Synchronous Primary Vulvar Squamous Cell Carcinoma and Ciliated Cell Variant of Endometrioid Adenocarcinoma Arising in an Endometrial Polyp: A Rare Dual Malignancy Cureus

Published: Aug. 12, 2025, 5:45 p.m.
Organon Ends Development of OG-6219 After Endometriosis Trial Fails to Meet Primary Endpoint - MarketScreener

Organon Ends Development of OG-6219 After Endometriosis Trial Fails to Meet Primary Endpoint MarketScreener

Published: July 2, 2025, 12:10 p.m.
Organon ELENA trial misses primary endpoint, to discontinue OG-6219 program - TipRanks

Organon ELENA trial misses primary endpoint, to discontinue OG-6219 program TipRanks

Published: July 2, 2025, 11:54 a.m.
DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer - BioSpace

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer BioSpace

Published: June 9, 2025, 12:43 p.m.
DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer | AZN Stock News - GuruFocus

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer | AZN Stock News GuruFocus

Published: June 9, 2025, 12:18 p.m.
Daewon Pharm’s uterine fibroid drug meets primary endpoint in P2 trial - koreabiomed.com

Daewon Pharm’s uterine fibroid drug meets primary endpoint in P2 trial koreabiomed.com

Published: May 7, 2025, 6:51 a.m.
Endometriosis presenting as a rectal stricture in a patient with ulcerative colitis and primary sclerosing cholangitis: A case report - Frontiers

Endometriosis presenting as a rectal stricture in a patient with ulcerative colitis and primary sclerosing cholangitis: A case report Frontiers

Published: April 22, 2025, 9:22 a.m.
Dostarlimab/Chemo Earns Expanded Canadian Approval in Primary Advanced, First Recurrent Endometrial Cancer - OncLive

Dostarlimab/Chemo Earns Expanded Canadian Approval in Primary Advanced, First Recurrent Endometrial Cancer OncLive

Published: April 18, 2025, 3:54 p.m.
Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - BioSpace

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …

Published: April 18, 2025, 5:25 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!